172,794 research outputs found

    Fisheries resource management in the OECS: some perspective

    Get PDF

    Reutilization and Legal Protection of Non-Copyrightable Database Contents

    Get PDF
    The availability of data on the web and the improvement of technologies have made it increasingly easy to reuse existing data to create new databases and provide value-added services. Meanwhile, initial database creators have been seeking legal protection for their data. After presenting a brief history of legislation related to legal protection for non-copyrightable database contents, we discuss challenging issues to be considered in formulating a database protection regulation. These issues can be addressed from the perspective of economics. Results from a preliminary economic analysis are presented. The findings indicate that depending on investment required to create the initial database and the level of differentiation between the initial database and the reuser database, the choice of a social welfare-enhancing regulation can allow for no reuse, free reuse, or fee-paying reuse

    ICTs, Business Regulation and Economic Development : A Cross-country Examination

    Get PDF
    Government regulation of business activity has been recognized as having critical impact on countries economic development. The aim of this research is to empirically explore the role played by information and communication technology (ICT) on the regulatory environment for doing business at the country level. We expect that the greater the access to information, the better the regulatory framework for doing business which can in turn have a positive impact on economic performance. Further, we intend to assess the extent to which ICT measures mediate the effect of business regulation on countries’ economic performance as measured by GDP per capita. This undergoing research is based on empirical evidence from two databases of the World Bank namely the Doing Business Database and the World Development Indicators database both of which had their most recent release in September 2008. Preliminary results using data corresponding to the year 2005 support our hypotheses

    Preliminary Report on Patent Literature, Search Methodology and Patent Status of Medicines on the WHO EML 2009

    Get PDF
    Over the past several decades the World Health Organization (WHO) has produced the Essential Medicines List (EML) to assist countries in deciding what medicines should be essential and available in National Essential Medicine Lists.1 WHO, through the work of regional offices, supports nations using the EML to ensure the quality, availability, and affordability of pharmaceuticals required to promote and advance public health in nations across the globe. However in some cases, access to EML pharmaceuticals might be complicated by existing patents, i.e., where issued, patent rights might pose obstacles to access and inclusion in national EMLs. Indeed, in developed and emerging economy national jurisdictions patent protection may be in effect for a not insignificant number of the WHO EML pharmaceuticals (Figure 2A). However, in developing countries, it is uncertain whether these patents have been filed or issued. Without patent data predicated on an established, reproducible protocol for accessing and assembling patent information on the EML pharmaceuticals, discussions, debates and strategic approaches to understanding and managing patents with regard to access and delivery to developing countries remain in the dark. Indeed, it is absurd to make policy and formulate strategy without solid patent information: the critical foundation for rational debate. To analyze the degree and scope of patenting of EML pharmaceuticals, WIPO (with WHO) approached the Franklin Pierce Center for Intellectual Property at the University of New Hampshire School of Law, specifically the International Technology Transfer Institute (ITTI) to generate a preliminary overview of patents appurtenant to recently added pharmaceutical updates to the EML.2 As part of this work, with inputs from WHO and WIPO, ITTI developed novel methodology and a detailed protocol for identifying EML pharmaceutical patents in national jurisdictions, with an easily reproducible yet cost effective template. Herein is described the development of such a protocol and a preliminary pool of patent information that illustrates its utility. The protocol yields data in a layered approach thereby allowing a user to quickly and effectively obtain both broad and detailed patent information for medications on the WHO EML. In addition, the protocol can be used as an initial path for targeted strategic analysis of potentially relevant patent information in national jurisdictions. In sum, the objectives for this project were: To develop a robust methodology to assess the patent status of medicines on the WHO Model List of Essential Medicines; To place in the public domain a detailed report on the present (2010) patent status of medicines that were on patent in 2003 and those medicines added to the Model List since 2003 by country and level of development; and To analyze the patent status of these Essential Medicines by the development status of countries. The report describes the development of the protocol and presents a preliminary list of EML and corresponding patents in certain jurisdictions to illustrate the utility of the approach. Results will be discussed both in terms of global access and patents, and in the context of establishing standard, systematic, protocols for periodic patent searches related to EML content. 1 WORLD HEALTH ORGANIZATION, CONTINUITY AND CHANGE IMPLEMENTING THE THIRD WHO MEDICINES STRATEGY 2008--‐2013 20 (WHO Press, 3rd ed. 2009). 2 This report covers the EML up to and including updates until 2009

    Expanding Paramedicine in the Community (EPIC): study protocol for a randomized controlled trial.

    Get PDF
    BackgroundThe incidence of chronic diseases, including diabetes mellitus (DM), heart failure (HF) and chronic obstructive pulmonary disease (COPD) is on the rise. The existing health care system must evolve to meet the growing needs of patients with these chronic diseases and reduce the strain on both acute care and hospital-based health care resources. Paramedics are an allied health care resource consisting of highly-trained practitioners who are comfortable working independently and in collaboration with other resources in the out-of-hospital setting. Expanding the paramedic's scope of practice to include community-based care may decrease the utilization of acute care and hospital-based health care resources by patients with chronic disease.Methods/designThis will be a pragmatic, randomized controlled trial comparing a community paramedic intervention to standard of care for patients with one of three chronic diseases. The objective of the trial is to determine whether community paramedics conducting regular home visits, including health assessments and evidence-based treatments, in partnership with primary care physicians and other community based resources, will decrease the rate of hospitalization and emergency department use for patients with DM, HF and COPD. The primary outcome measure will be the rate of hospitalization at one year. Secondary outcomes will include measures of health system utilization, overall health status, and cost-effectiveness of the intervention over the same time period. Outcome measures will be assessed using both Poisson regression and negative binomial regression analyses to assess the primary outcome.DiscussionThe results of this study will be used to inform decisions around the implementation of community paramedic programs. If successful in preventing hospitalizations, it has the ability to be scaled up to other regions, both nationally and internationally. The methods described in this paper will serve as a basis for future work related to this study.Trial registrationClinicalTrials.gov: NCT02034045. Date: 9 January 2014

    Options for meeting longitudinal information needs: a preliminary investigation

    Get PDF
    The aim of this paper is to identify the main future requirements for longitudinal data for research and policy purposes, and to discuss how well existing data sources could meet these requirements, as well as options for addressing the gaps. Our focus is on longitudinal information needs relating to individuals, families, and households. Information needs relating to businesses are outside the scope of this paper.&nbsp

    Harmonising Databases for the Cross National Study of Internal Migration: Lessons from Australia and Britain

    Get PDF
    This project involves the development of a Web interface to origin-destination statistics from the 1991 Census (in a form that will be compatible with planned 2001 outputs). It provides the user with a set of screen-based tools for setting the parameters governing each data extraction (data set, areas, variables) in the form of a query. Traffic light icons are used to signal what the user has set so far and what remains to be done. There are options to extract different types of flow data and to generate output in different formats. The system can now be used to access the interaction flow data contained in the 1991 Special Migration Statistics Sets 1 and 2 and Special Workplace Statistics Set C. WICID has been demonstrated at the Origin-Destination Statistics Roadshows organised by GRO Scotland and held during May/June 2000 and the Census Offices have expressed interest in using the software in the Census Access Project

    How to Undertake a Clinically Relevant Systematic Review in a Rapidly Evolving Field: Magnetic Resonance Angiography

    Get PDF
    Objectives: The aim was to determine which generations of the evolving technology of magnetic resonance angiography (MRA) are currently of clinical relevance in two clinical applications. Our purpose was to plan a systematic review that would be valuable both to purchasers driven by cost-effectiveness and to practicing clinicians. Methods: Information was gathered from a search of major bibliographic databases, from a short questionnaire sent to 500 U.K. vascular radiologists and vascular surgeons, and from local clinical The authors thank A. Jackson and all those who completed a questionnaire. This work was carried out with the financial support of the Secretary of State for Health under the NHS Health Technology Assessment Programme, project 97/13/04. The views and opinions expressed do not necessarily reflect those of the Secretary of State for Health. In part, this work was undertaken by the Leeds Teaching Hospitals NHS Trust, which received funding from the NHS Executive. The views expressed in this publication are those of the authors and not necessarily those of the NHS Executive.experts. We asked which of the MRA techniques were currently used and, assuming availability, what would be their technique of choice. Results: There were 206 published articles that satisfied preliminary inclusion criteria: 69 discussed 2D time of flight (TOF); 47, 3D TOF; and 38, contrast-enhanced techniques. There were 162 questionnaires returned (60 radiologists, 102 surgeons). Of the total respondents, 77/162 (48%) used MRA in the assessment of carotid artery stenosis; 47/77 (61%) used 2D TOF; 32/77 (42%), 3D TOF; and 26/77 (34%), contrast-enhanced techniques. Thirty-five of 162 (22%) respondents used MRA in the assessment of peripheral vascular disease (PVD); 15/35 (43%) used 2D TOF, 4/35 (11%) used 3D TOF, and 22/35 (63%) used contrast-enhanced techniques. For those wishing to use MRA, contrast-enhanced techniques were the method of choice. Conclusions: The TOF methods that represent earlier generations of the technology remain clinically relevant, and will therefore be included in our systematic review. To ensure complete and relevant coverage in reviews of other evolving technologies, it would be advisable to obtain data for guidance in a similar way
    corecore